MedTrace Logo

Hormonal Contraception and Vaginal Health

NCT00612508 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-11-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring).

Conditions

  • Contraceptive Usage
  • Vaginal Epithelial Disruption

Interventions

DRUG

Desogen (ethinyl estradiol and desogestrel)

1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol

DRUG

NuvaRing (ethinyl estradiol and etonogestrel)

Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring

Sponsors & Collaborators

  • Oregon Clinical and Translational Research Institute

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Jeffrey T Jensen, MD., MPH · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612508 on ClinicalTrials.gov